145 related articles for article (PubMed ID: 36637933)
1. Simultaneous treatment of two lung cancer lesions with stereotactic MR-guided adaptive radiation therapy: A case report.
Chen F; Cheng YK; Chiang CH; Lu TY; Huang CJ
Medicine (Baltimore); 2023 Jan; 102(2):e32626. PubMed ID: 36637933
[TBL] [Abstract][Full Text] [Related]
2. Local control and toxicity after magnetic resonance imaging (MR)-guided single fraction lung stereotactic ablative radiotherapy.
Tekatli H; Palacios MA; Schneiders FL; Haasbeek CJA; Slotman BJ; Lagerwaard FJ; Senan S
Radiother Oncol; 2023 Oct; 187():109823. PubMed ID: 37516364
[TBL] [Abstract][Full Text] [Related]
3. Application of real-time MRI-guided linear accelerator in stereotactic ablative body radiotherapy for non-small cell lung cancer: one step forward to precise targeting.
Kang HJ; Kwak YK; Kim M; Lee SJ
J Cancer Res Clin Oncol; 2022 Nov; 148(11):3215-3223. PubMed ID: 36040666
[TBL] [Abstract][Full Text] [Related]
4. Long-Term Outcomes of Salvage Stereotactic Ablative Radiotherapy for Isolated Lung Recurrence of Non-Small Cell Lung Cancer: A Phase II Clinical Trial.
Sun B; Brooks ED; Komaki R; Liao Z; Jeter M; McAleer M; Balter PA; Welsh JD; O'Reilly M; Gomez D; Hahn SM; Sepesi B; Rice DC; Heymach JV; Chang JY
J Thorac Oncol; 2017 Jun; 12(6):983-992. PubMed ID: 28259750
[TBL] [Abstract][Full Text] [Related]
5. Role of On-Table Plan Adaptation in MR-Guided Ablative Radiation Therapy for Central Lung Tumors.
Finazzi T; Palacios MA; Spoelstra FOB; Haasbeek CJA; Bruynzeel AME; Slotman BJ; Lagerwaard FJ; Senan S
Int J Radiat Oncol Biol Phys; 2019 Jul; 104(4):933-941. PubMed ID: 30928360
[TBL] [Abstract][Full Text] [Related]
6. Differentiation of tumor recurrence from radiation-induced pulmonary fibrosis after stereotactic ablative radiotherapy for lung cancer: characterization of 18F-FDG PET/CT findings.
Nakajima N; Sugawara Y; Kataoka M; Hamamoto Y; Ochi T; Sakai S; Takahashi T; Kajihara M; Teramoto N; Yamashita M; Mochizuki T
Ann Nucl Med; 2013 Apr; 27(3):261-70. PubMed ID: 23299492
[TBL] [Abstract][Full Text] [Related]
7. Planning Target Volume D95 and Mean Dose Should Be Considered for Optimal Local Control for Stereotactic Ablative Radiation Therapy.
Zhao L; Zhou S; Balter P; Shen C; Gomez DR; Welsh JD; Lin SH; Chang JY
Int J Radiat Oncol Biol Phys; 2016 Jul; 95(4):1226-35. PubMed ID: 27209498
[TBL] [Abstract][Full Text] [Related]
8. Outcomes of stereotactic ablative radiotherapy in patients with potentially operable stage I non-small cell lung cancer.
Lagerwaard FJ; Verstegen NE; Haasbeek CJ; Slotman BJ; Paul MA; Smit EF; Senan S
Int J Radiat Oncol Biol Phys; 2012 May; 83(1):348-53. PubMed ID: 22104360
[TBL] [Abstract][Full Text] [Related]
9. Comparison of treatment plans between IMRT with MR-linac and VMAT for lung SABR.
Park JM; Wu HG; Kim HJ; Choi CH; Kim JI
Radiat Oncol; 2019 Jun; 14(1):105. PubMed ID: 31196120
[TBL] [Abstract][Full Text] [Related]
10. Prostate-specific membrane antigen-positron emission tomography/computed tomography (PSMA-PET/CT)-guided stereotactic ablative body radiotherapy for oligometastatic prostate cancer: a single-institution experience and review of the published literature.
Ong WL; Koh TL; Lim Joon D; Chao M; Farrugia B; Lau E; Khoo V; Lawrentschuk N; Bolton D; Foroudi F
BJU Int; 2019 Nov; 124 Suppl 1():19-30. PubMed ID: 31507035
[TBL] [Abstract][Full Text] [Related]
11. Residual ¹⁸F-FDG-PET uptake 12 weeks after stereotactic ablative radiotherapy for stage I non-small-cell lung cancer predicts local control.
Bollineni VR; Widder J; Pruim J; Langendijk JA; Wiegman EM
Int J Radiat Oncol Biol Phys; 2012 Jul; 83(4):e551-5. PubMed ID: 22417800
[TBL] [Abstract][Full Text] [Related]
12. MR-Linac guided adaptive stereotactic ablative body radiotherapy for recurrent cardiac sarcoma with mitral valve bioprosthesis - a case report.
Batumalai V; Carr M; Jameson M; Crawford D; Jelen U; Pagulayan C; Twentyman T; Hong A; de Leon J
J Med Radiat Sci; 2023 Jun; 70(2):199-205. PubMed ID: 36890690
[TBL] [Abstract][Full Text] [Related]
13. Clinical outcome and predictors of survival and pneumonitis after stereotactic ablative radiotherapy for stage I non-small cell lung cancer.
Chang JY; Liu H; Balter P; Komaki R; Liao Z; Welsh J; Mehran RJ; Roth JA; Swisher SG
Radiat Oncol; 2012 Sep; 7():152. PubMed ID: 22963661
[TBL] [Abstract][Full Text] [Related]
14. Variation in Lung Tumour Breathing Motion between Planning Four-dimensional Computed Tomography and Stereotactic Ablative Radiotherapy Delivery and its Dosimetric Implications: Any Role for Four-dimensional Set-up Verification?
Ruben JD; Seeley A; Panettieri V; Ackerly T
Clin Oncol (R Coll Radiol); 2016 Jan; 28(1):21-7. PubMed ID: 26432188
[TBL] [Abstract][Full Text] [Related]
15. Clinical Outcomes of Stereotactic MR-Guided Adaptive Radiation Therapy for High-Risk Lung Tumors.
Finazzi T; Haasbeek CJA; Spoelstra FOB; Palacios MA; Admiraal MA; Bruynzeel AME; Slotman BJ; Lagerwaard FJ; Senan S
Int J Radiat Oncol Biol Phys; 2020 Jun; 107(2):270-278. PubMed ID: 32105742
[TBL] [Abstract][Full Text] [Related]
16. Clinical outcomes and lung toxicities after lung SABR using dynamic conformal arc therapy: a single-institution cohort study.
Mesny E; Ayadi M; Dupuis P; Beldjoudi G; Tanguy R; Martel-Lafay I
Radiat Oncol; 2023 Feb; 18(1):36. PubMed ID: 36814265
[TBL] [Abstract][Full Text] [Related]
17. 7-year follow-up after stereotactic ablative radiotherapy for patients with stage I non-small cell lung cancer: Results of a phase 2 clinical trial.
Sun B; Brooks ED; Komaki RU; Liao Z; Jeter MD; McAleer MF; Allen PK; Balter PA; Welsh JD; O'Reilly MS; Gomez D; Hahn SM; Roth JA; Mehran RJ; Heymach JV; Chang JY
Cancer; 2017 Aug; 123(16):3031-3039. PubMed ID: 28346656
[TBL] [Abstract][Full Text] [Related]
18. Optimizing SABR delivery for synchronous multiple lung tumors using volumetric-modulated arc therapy.
Tekatli H; Tetar SU; Nguyen TK; Warner A; Verbakel WF; Palma DA; Dahele M; Gaede S; Haasbeek C; Spoelstra FO; de Haan PF; Slotman BJ; Senan S
Acta Oncol; 2017 Apr; 56(4):548-554. PubMed ID: 28358667
[TBL] [Abstract][Full Text] [Related]
19. Patterns of disease recurrence after stereotactic ablative radiotherapy for early stage non-small-cell lung cancer: a retrospective analysis.
Senthi S; Lagerwaard FJ; Haasbeek CJ; Slotman BJ; Senan S
Lancet Oncol; 2012 Aug; 13(8):802-9. PubMed ID: 22727222
[TBL] [Abstract][Full Text] [Related]
20. Pre-treatment non-target lung FDG-PET uptake predicts symptomatic radiation pneumonitis following Stereotactic Ablative Radiotherapy (SABR).
Chaudhuri AA; Binkley MS; Rigdon J; Carter JN; Aggarwal S; Dudley SA; Qian Y; Kumar KA; Hara WY; Gensheimer M; Nair VS; Maxim PG; Shultz DB; Bush K; Trakul N; Le QT; Diehn M; Loo BW; Guo HH
Radiother Oncol; 2016 Jun; 119(3):454-60. PubMed ID: 27267049
[TBL] [Abstract][Full Text] [Related]
[Next] [New Search]